Zacks: Brokerages Expect Viking Therapeutics Inc (NASDAQ:VKTX) Will Announce Earnings of -$0.13 Per Share
Equities research analysts forecast that Viking Therapeutics Inc (NASDAQ:VKTX) will report earnings of ($0.13) per share for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Viking Therapeutics’ earnings. The lowest EPS estimate is ($0.17) and the highest is ($0.11). Viking Therapeutics reported earnings of ($0.11) per share during the same quarter last year, which would indicate a negative year-over-year growth rate of 18.2%. The company is expected to report its next quarterly earnings report on Wednesday, November 6th.
On average, analysts expect that Viking Therapeutics will report full-year earnings of ($0.46) per share for the current year, with EPS estimates ranging from ($0.61) to ($0.40). For the next year, analysts expect that the business will post earnings of ($0.69) per share, with EPS estimates ranging from ($0.96) to ($0.47). Zacks’ earnings per share averages are an average based on a survey of research analysts that cover Viking Therapeutics.
Viking Therapeutics (NASDAQ:VKTX) last announced its quarterly earnings results on Thursday, August 1st. The biotechnology company reported ($0.11) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.02).
NASDAQ VKTX traded down $0.20 during trading on Friday, reaching $6.83. 11,380 shares of the company’s stock were exchanged, compared to its average volume of 2,445,925. The firm’s 50 day simple moving average is $7.90. The firm has a market capitalization of $507.64 million, a PE ratio of -17.12 and a beta of 2.29. Viking Therapeutics has a fifty-two week low of $6.68 and a fifty-two week high of $24.00.
Institutional investors have recently bought and sold shares of the company. Geode Capital Management LLC grew its position in shares of Viking Therapeutics by 30.6% in the fourth quarter. Geode Capital Management LLC now owns 594,510 shares of the biotechnology company’s stock valued at $4,548,000 after purchasing an additional 139,420 shares during the last quarter. Marshall Wace North America L.P. acquired a new position in shares of Viking Therapeutics in the first quarter valued at approximately $880,000. Hikari Power Ltd boosted its stake in shares of Viking Therapeutics by 25.0% in the first quarter. Hikari Power Ltd now owns 50,000 shares of the biotechnology company’s stock valued at $497,000 after buying an additional 10,000 shares during the period. BNP Paribas Arbitrage SA bought a new stake in shares of Viking Therapeutics in the first quarter valued at approximately $126,000. Finally, Bailard Inc. boosted its stake in shares of Viking Therapeutics by 109.5% in the first quarter. Bailard Inc. now owns 312,200 shares of the biotechnology company’s stock valued at $3,103,000 after buying an additional 163,200 shares during the period. 62.91% of the stock is currently owned by institutional investors.
About Viking Therapeutics
Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta, which is in Phase II clinical trials to treat patients with non-alcoholic fatty liver disease and elevated low-density lipoprotein cholesterol.
Further Reading: What is the CBOE Russell 2000® Volatility Index?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Viking Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.